Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase

Citation
A. Esteban-gamboa et al., Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase, J MED CHEM, 43(5), 2000, pp. 971-983
Citations number
43
Categorie Soggetti
Chemistry & Analysis
Journal title
JOURNAL OF MEDICINAL CHEMISTRY
ISSN journal
00222623 → ACNP
Volume
43
Issue
5
Year of publication
2000
Pages
971 - 983
Database
ISI
SICI code
0022-2623(20000309)43:5<971:DSAEEO>2.0.ZU;2-8
Abstract
A series of acyclic phosphonate derivatives of thymine has been synthesized and tested as multisubstrate analogue inhibitors of Escherichia colt thymi dine phosphorylase. The compounds synthesized include 1-(phosphonoalkyl)thy mines with six to nine methylenes (1-4, respectively); 1-[(Z)-4-phosphonome thoxy-2-butenyl]thymine (5) and its butyl and 2,3-cis-dihydroxybutyl deriva tives (6 and 7, respectively); 1-[(Z)-(4-(phosphonomethoxy)methoxy)-2-buten yl]thymine (8) and also its butyl and 2,3-cis-dihydroxybutyl analogues (9 a nd 10); and 1-[((Z)-4-(phosphonomethoxy)-2-butenoxy)methyl]thymine(11), Eva luation of these compounds against E. coli revealed significant enzymatic i nhibition by 2, 3, 4, 6, and 8 at a concentration of 1000 mu M, 3 and 4 bei ng the most potent. Replacement of the thymine base in 3 by 6-amino-5-bromo uracil and 7-deazaxanthine afforded compounds 12 and 13, which showed a pro nounced improvement of TPase inhibition, comparable to 7-deazaxanthine. Whe n inorganic phosphate was used as a variable substrate, compounds 12 and 13 displayed competitive kinetics with respect to phosphate, indicating a dir ect interaction of these compounds with the phosphate binding site. Also co mpounds 12 and 13 were found to be competitive inhibitors of TPase against thymidine as a variable substrate. These results are consistent with the co mpounds being multisubstrate analogue inhibitors of E. coli TPase, and they represent the first example of such TPase inhibitors.